Abstract
Objective: This Phase II study was conducted to evaluate the activity and feasibility of a regimen of nedaplatin and 5-fluorouracil as induction chemotherapy, followed by intensitymodulated radiotherapy concurrent with chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Methods: Patients received neoadjuvant chemotherapy comprised two cycles of 5-fluorouracil at 700 mg/m2/day administered on days 1-4 as continuous intravenous infusion and nedaplatin (100 mg/m2 administered i.v. over 2 h) given after the administration of 5-fluorouracil on day 1, repeated every 3 weeks, followed by intensity-modulated radiotherapy concurrent with nedaplatin. During intensity-modulated radiotherapy, nedaplatin was administered at a dose of 100 mg/m2 intravenous infusion on days 1, 22 and 43, given ~60 min before radiation. Results: Fifty-nine (95.8%) of the 60 patients were assessable for response. Thirty-eight cases of complete response and 14 cases of partial response were confirmed after completion of chemoradiation, with the objective response rate of 86.7% (95% CI, 78.1-95.3%). The median follow-up period was 48 months (range, 30-62 months). The 3-year progression-free survival and overall survival were 75.0% (95% CI, 63.0-87.0%) and 85.5% (95% CI, 75.9-95.1%). No patient showed Grade 3 or higher renal dysfunction. The most commonly observed late effect was xerostomia, but the severity diminished over time, and the detectable xerostomia at 24 months was 10.2%. There were no treatment-related deaths during this study. Conclusions: Neoadjuvant chemotherapy with nedaplatin and 5-fluorouracil followed by concomitant nedaplatin and intensity-modulated radiotherapy is an effective and safe treatment for Southern China patients affected by locoregionally advanced nasopharyngeal carcinoma.
Original language | English |
---|---|
Article number | hyp183 |
Pages (from-to) | 425-431 |
Number of pages | 7 |
Journal | Japanese Journal of Clinical Oncology |
Volume | 40 |
Issue number | 5 |
DOIs | |
State | Published - Jan 19 2010 |
ASJC Scopus Subject Areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research
Keywords
- Chemo-Phase II
- Head and neck
- Radiation oncology
Access to Document
10.1093/jjco/hyp183License: Unspecified
OpenUrl availability
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Zheng, J., Wang, G., Yang, G. Y., Wang, D., Luo, X., Chen, C., Zhang, Z., Li, Q., Xu, W., Li, Z., & Wang, D. (2010). Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Japanese Journal of Clinical Oncology, 40(5), 425-431. Article hyp183. https://doi.org/10.1093/jjco/hyp183
Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. / Zheng, Jijun; Wang, Ge; Yang, Gary Y. et al.
In: Japanese Journal of Clinical Oncology, Vol. 40, No. 5, hyp183, 19.01.2010, p. 425-431.
Research output: Contribution to journal › Article › peer-review
Zheng, J, Wang, G, Yang, GY, Wang, D, Luo, X, Chen, C, Zhang, Z, Li, Q, Xu, W, Li, Z & Wang, D 2010, 'Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma', Japanese Journal of Clinical Oncology, vol. 40, no. 5, hyp183, pp. 425-431. https://doi.org/10.1093/jjco/hyp183
Zheng J, Wang G, Yang GY, Wang D, Luo X, Chen C et al. Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Japanese Journal of Clinical Oncology. 2010 Jan 19;40(5):425-431. hyp183. doi: 10.1093/jjco/hyp183
Zheng, Jijun ; Wang, Ge ; Yang, Gary Y. et al. / Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. In: Japanese Journal of Clinical Oncology. 2010 ; Vol. 40, No. 5. pp. 425-431.
@article{e5a0d133f6b74936a3eb3b0633eca368,
title = "Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma",
abstract = "Objective: This Phase II study was conducted to evaluate the activity and feasibility of a regimen of nedaplatin and 5-fluorouracil as induction chemotherapy, followed by intensitymodulated radiotherapy concurrent with chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Methods: Patients received neoadjuvant chemotherapy comprised two cycles of 5-fluorouracil at 700 mg/m2/day administered on days 1-4 as continuous intravenous infusion and nedaplatin (100 mg/m2 administered i.v. over 2 h) given after the administration of 5-fluorouracil on day 1, repeated every 3 weeks, followed by intensity-modulated radiotherapy concurrent with nedaplatin. During intensity-modulated radiotherapy, nedaplatin was administered at a dose of 100 mg/m2 intravenous infusion on days 1, 22 and 43, given ~60 min before radiation. Results: Fifty-nine (95.8%) of the 60 patients were assessable for response. Thirty-eight cases of complete response and 14 cases of partial response were confirmed after completion of chemoradiation, with the objective response rate of 86.7% (95% CI, 78.1-95.3%). The median follow-up period was 48 months (range, 30-62 months). The 3-year progression-free survival and overall survival were 75.0% (95% CI, 63.0-87.0%) and 85.5% (95% CI, 75.9-95.1%). No patient showed Grade 3 or higher renal dysfunction. The most commonly observed late effect was xerostomia, but the severity diminished over time, and the detectable xerostomia at 24 months was 10.2%. There were no treatment-related deaths during this study. Conclusions: Neoadjuvant chemotherapy with nedaplatin and 5-fluorouracil followed by concomitant nedaplatin and intensity-modulated radiotherapy is an effective and safe treatment for Southern China patients affected by locoregionally advanced nasopharyngeal carcinoma.",
keywords = "Chemo-Phase II, Head and neck, Radiation oncology",
author = "Jijun Zheng and Ge Wang and Yang, {Gary Y.} and Daoyuan Wang and Xizhong Luo and Chuan Chen and Zhimin Zhang and Qiong Li and Wen Xu and Zengpeng Li and Dong Wang",
note = "Funding Information: The research was supported in part by grants from the National Science Foundation of China (No. 30370341 and No. 30570410) and the Academic Foundation for Authors of National Excellent Doctoral Dissertation of China (No. 200261).",
year = "2010",
month = jan,
day = "19",
doi = "10.1093/jjco/hyp183",
language = "English",
volume = "40",
pages = "425--431",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
number = "5",
}
TY - JOUR
T1 - Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma
AU - Zheng, Jijun
AU - Wang, Ge
AU - Yang, Gary Y.
AU - Wang, Daoyuan
AU - Luo, Xizhong
AU - Chen, Chuan
AU - Zhang, Zhimin
AU - Li, Qiong
AU - Xu, Wen
AU - Li, Zengpeng
AU - Wang, Dong
N1 - Funding Information:The research was supported in part by grants from the National Science Foundation of China (No. 30370341 and No. 30570410) and the Academic Foundation for Authors of National Excellent Doctoral Dissertation of China (No. 200261).
PY - 2010/1/19
Y1 - 2010/1/19
N2 - Objective: This Phase II study was conducted to evaluate the activity and feasibility of a regimen of nedaplatin and 5-fluorouracil as induction chemotherapy, followed by intensitymodulated radiotherapy concurrent with chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Methods: Patients received neoadjuvant chemotherapy comprised two cycles of 5-fluorouracil at 700 mg/m2/day administered on days 1-4 as continuous intravenous infusion and nedaplatin (100 mg/m2 administered i.v. over 2 h) given after the administration of 5-fluorouracil on day 1, repeated every 3 weeks, followed by intensity-modulated radiotherapy concurrent with nedaplatin. During intensity-modulated radiotherapy, nedaplatin was administered at a dose of 100 mg/m2 intravenous infusion on days 1, 22 and 43, given ~60 min before radiation. Results: Fifty-nine (95.8%) of the 60 patients were assessable for response. Thirty-eight cases of complete response and 14 cases of partial response were confirmed after completion of chemoradiation, with the objective response rate of 86.7% (95% CI, 78.1-95.3%). The median follow-up period was 48 months (range, 30-62 months). The 3-year progression-free survival and overall survival were 75.0% (95% CI, 63.0-87.0%) and 85.5% (95% CI, 75.9-95.1%). No patient showed Grade 3 or higher renal dysfunction. The most commonly observed late effect was xerostomia, but the severity diminished over time, and the detectable xerostomia at 24 months was 10.2%. There were no treatment-related deaths during this study. Conclusions: Neoadjuvant chemotherapy with nedaplatin and 5-fluorouracil followed by concomitant nedaplatin and intensity-modulated radiotherapy is an effective and safe treatment for Southern China patients affected by locoregionally advanced nasopharyngeal carcinoma.
AB - Objective: This Phase II study was conducted to evaluate the activity and feasibility of a regimen of nedaplatin and 5-fluorouracil as induction chemotherapy, followed by intensitymodulated radiotherapy concurrent with chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Methods: Patients received neoadjuvant chemotherapy comprised two cycles of 5-fluorouracil at 700 mg/m2/day administered on days 1-4 as continuous intravenous infusion and nedaplatin (100 mg/m2 administered i.v. over 2 h) given after the administration of 5-fluorouracil on day 1, repeated every 3 weeks, followed by intensity-modulated radiotherapy concurrent with nedaplatin. During intensity-modulated radiotherapy, nedaplatin was administered at a dose of 100 mg/m2 intravenous infusion on days 1, 22 and 43, given ~60 min before radiation. Results: Fifty-nine (95.8%) of the 60 patients were assessable for response. Thirty-eight cases of complete response and 14 cases of partial response were confirmed after completion of chemoradiation, with the objective response rate of 86.7% (95% CI, 78.1-95.3%). The median follow-up period was 48 months (range, 30-62 months). The 3-year progression-free survival and overall survival were 75.0% (95% CI, 63.0-87.0%) and 85.5% (95% CI, 75.9-95.1%). No patient showed Grade 3 or higher renal dysfunction. The most commonly observed late effect was xerostomia, but the severity diminished over time, and the detectable xerostomia at 24 months was 10.2%. There were no treatment-related deaths during this study. Conclusions: Neoadjuvant chemotherapy with nedaplatin and 5-fluorouracil followed by concomitant nedaplatin and intensity-modulated radiotherapy is an effective and safe treatment for Southern China patients affected by locoregionally advanced nasopharyngeal carcinoma.
KW - Chemo-Phase II
KW - Head and neck
KW - Radiation oncology
UR - http://www.scopus.com/inward/record.url?scp=77952559137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952559137&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyp183
DO - 10.1093/jjco/hyp183
M3 - Article
C2 - 20085903
SN - 0368-2811
VL - 40
SP - 425
EP - 431
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
IS - 5
M1 - hyp183
ER -